Amgen (GB:0R0T)

Amgen (0R0T) Income Statement


Amgen Income Statement

Last quarter (Q4 2023), Amgen's total revenue was $8.20B, an increase of 19.84% from the same quarter last year. In Q4, Amgen's net income was $307.00M. See Amgen’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 28.19B$ 28.19B$ 26.32B$ 25.98B$ 25.42B$ 23.36B
Cost of Revenue
$ 8.60B$ 8.45B$ 6.41B$ 6.45B$ 6.16B$ 4.36B
Gross Profit
$ 19.59B$ 19.74B$ 19.92B$ 19.52B$ 19.27B$ 19.01B
Operating Expense
$ 11.84B$ 11.84B$ 10.35B$ 11.89B$ 10.13B$ 9.33B
Operating Income
$ 7.90B$ 7.90B$ 9.57B$ 7.64B$ 9.14B$ 9.67B
Net Non Operating Interest Income Expense
$ -811.00M$ -2.88B$ -1.41B$ -938.00M$ -1.26B$ -536.00M
Other Income Expense
$ -923.00M$ -2.83B$ 814.00M$ -26.15B$ 256.00M-
Pretax Income
$ 7.86B$ 7.86B$ 7.35B$ 6.70B$ 8.13B$ 9.14B
Tax Provision
$ 1.14B$ 1.14B$ 794.00M$ 808.00M$ 869.00M$ 1.30B
Earnings From Equity Interest Net Of Tax
$ -11.00M$ -11.00M$ -891.00M---
Net Income Common Stockholders
$ 6.42B$ 6.72B$ 6.55B$ 5.89B$ 7.26B$ 7.84B
Basic EPS
----$ 12.40$ 12.96
Diluted EPS
----$ 12.31$ 12.88
Basic Average Shares
----$ 586.00M$ 605.00M
Diluted Average Shares
----$ 590.00M$ 609.00M
Dividend Per Share
----$ 6.40$ 5.80
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
----$ 16.60$ 14.82
Rent Expense Supplemental
Total Expenses
$ 20.44B$ 20.29B$ 16.76B$ 18.34B$ 16.29B$ 13.69B
Net Income From Continuing And Discontinued Operation
$ 6.72B$ 6.72B$ 6.55B$ 5.89B$ 7.26B$ 7.84B
Normalized Income
$ 3.58B$ 6.31B$ 5.74B-$ 7.26B$ 7.84B
Interest Expense
----$ 1.26B$ 1.29B
$ 10.73B$ 10.73B$ 8.75B$ 6.70B$ 9.39B$ 10.43B
$ 14.80B$ 14.80B$ 12.17B$ 10.10B$ 13.00B$ 12.63B
Currency in USD

Amgen Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis